Seventy percent of breaches involving the California healthcare industry were due to unencrypted data on lost or stolen hardware or portable media, a problem that strong encryption would fix.
Seventy percent of breaches involving the California healthcare industry were due to unencrypted data on lost or stolen hardware or portable media, a problem that strong encryption would fix, according to the latest data breach report from the state's attorney general. Only 19% of such breaches occurred in other industries.
The state noted that it is still trying to make encryption mandatory for personal data in transit, but so far has been unsuccessful.
Healthcare's 25 breaches accounted for 15% of the total reported in the state during 2012 and 2013, according to the report.
Read more at FierceHealthIT: http://bit.ly/1s2KA9I
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
January 28th 2023The FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a previous Bruton tyrosine kinase (BTK) inhibitor.
Read More
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
January 27th 2023The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512